Back to top
more

Myriad Genetics (MYGN)

(Delayed Data from NSDQ)

$17.67 USD

17.67
938,289

+0.10 (0.57%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $17.66 -0.01 (-0.06%) 7:10 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Sriparna Ghosal headshot

Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

by Sriparna Ghosal

The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

Steer Clear Of These 5 Toxic Stocks Before It's Too Late

by Zacks Equity Research

Figuring out bloated toxic stocks on a consistent basis and discarding them at the right time is the key to successful investing.

Myriad Genetics (MYGN) Releases Favorable Prolaris Results

by Zacks Equity Research

This study result is a major breakthrough and is expected to strengthen Myriad Genetics' (MYGN) Oncology segment.

Myriad Genetics (MYGN) Files for myChoice CDx Test sPMA

by Zacks Equity Research

With the receipt of the regulatory approval, Myriad Genetics (MYGN) will be taking a major stride forward in its Oncology and Women's Health segment.

Myriad Genetics (MYGN) Misses Q2 Earnings & Revenue Estimates

by Zacks Equity Research

Myriad Genetics (MYGN) reports decline in Hereditary Cancer, GeneSight, Vectra and Prenatal revenues in Q2.

Myriad Genetics (MYGN) Misses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of -25.81% and -6.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Myriad Genetics (MYGN) Q2 Earnings Expected to Decline

by Zacks Equity Research

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myriad Genetics' GUIDED Clinical Trial Outcome Encouraging

by Zacks Equity Research

The result of this clinical trial is a major stride forward in Myriad Genetics' (MYGN) commitment toward strengthening its portfolio of depressive disorder treatments.

Myriad Genetics' Cancer Companion Diagnostic Test Gets FDA Nod

by Zacks Equity Research

Myriad Genetics (MYGN) expands the use of BRACAnalysis CDx as a companion diagnostic test for metastatic pancreatic cancer with the receipt of the FDA clearance.

Myriad Genetics Presents Trial Outcomes in Breast Health

by Zacks Equity Research

Myriad Genetics' (MYGN) PRS enhances the detection of breast cancer risk in women having PV in high- and moderate-penetrance breast cancer genes.

Myriad Genetics Reports Favorable Study Result on Prequel

by Zacks Equity Research

Myriad Genetics (MYGN) posts breakthrough results on Prequel Prenatal Screen methodology, proving its superiority over traditional methods.

Myriad (MYGN) Up 18.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad's BRACAnalysis Wins HBOC Risk Assessment Nod in Japan

by Zacks Equity Research

The latest approval of Myriad Genetics' (MYGN) BRACAnalysis for HBOC risk assessment in Japan will further validate the superior standard of the BRACAnalysis Diagnostic System, globally.

Myriad Genetics' Test Added in Disease Activity Measure List

by Zacks Equity Research

Myriad Genetics' (MYGN) Vectra test receives recognition, with the inclusion in the list of recommended disease activity measures for RA patients.

Myriad Genetics Presents New Test Data in Autoimmune Segment

by Zacks Equity Research

Myriad Genetics (MYGN) presents key findings related to Vectra test from its autoimmune segment.

Company News For Nov 6, 2019

by Zacks Equity Research

Companies In The News Are: CPE, EVER, MYGN, AAN

Myriad Genetics (MYGN) Lags Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad Genetics (MYGN) observes a decline in Hereditary Cancer, GeneSight, Vectra as well as Other testing revenues in Q1.

Myriad Genetics (MYGN) Q1 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of -75.76% and -8.25%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Myriad Genetics (MYGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Myriad (MYGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Myriad Genetics Test to Identify Cancer Patients Gets FDA Nod

by Zacks Equity Research

Myriad Genetics (MYGN) moves a step toward advanced treatment by identifying women with ovarian cancer, who are currently receiving chemotherapy.

Myriad (MYGN) Up 5.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Myriad Genetics (MYGN) Q4 Earnings Lag Estimates, Revenues Up

by Zacks Equity Research

Myriad Genetics' (MYGN) overall Q4 performance is impressive, excepting weak sales at a few segments.

Myriad Genetics (MYGN) Lags Q4 Earnings and Revenue Estimates

by Zacks Equity Research

Myriad (MYGN) delivered earnings and revenue surprises of -12.77% and -2.81%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Can Cannabis Therapy Drive Canopy Growth's (CGC) Q1 Earnings?

by Zacks Equity Research

Canopy Growth (CGC) expects to deliver a strong first-quarter fiscal 2020 on solid performance by its cannabis therapy business.

What's in the Offing for Cisco Systems' (CSCO) Q4 Earnings?

by Zacks Equity Research

Cisco (CSCO) is benefiting from its expanding footprint in the rapidly growing security market. Also, partnerships and synergies from acquisitions will boost the company's revenue base.